BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Canaccord Adams' 27th Annual Global Growth Conference
Franklin, Tenn. – August 6, 2007 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it will deliver a presentation at the 27th Annual Canaccord Adams Global Growth Conference. Dr. Charles Hart, chief scientific officer, is scheduled to present to leading institutional investment representatives at 9:00 a.m. Eastern Time on August 8, 2007 at the Intercontinental Hotel in Boston, Mass.Dr. Hart will join executives from nearly 270 public and private companies for the conference, one of the longest-running institutional events focused exclusively on growth companies. A live audio webcast of the presentation will be available at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BMTI&item_id=1609683 and on the Company's website at www.biomimetics.com. The webcast will be accessible for a period of at least 30 days. About BioMimetic TherapeuticsBioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, periodontal, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S ®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. Additionally, the Company has clinical trials ongoing with its product candidates GEM OS®1 and GEM OS®2 in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the arm. The Company's product and lead product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration. For further information, visit www.biomimetics.com or contact Kearstin Patterson, corporate communications, at 615-236-4419.
Back to Headlines |
